UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New agents for Gram-positive bacteria

Current Opinion in Microbiology, 2000-10, Vol.3 (5), p.528-534

2000

Volltextzugriff (PDF)

Gatifloxacin and the elderly: pharmacokinetic–pharmacodynamic rationale for a potential age-related dose reduction

Journal of antimicrobial chemotherapy, 2003-09, Vol.52 (3), p.435-440

2003

Volltextzugriff (PDF)

Voriconazole Therapeutic Drug Monitoring

Antimicrobial Agents and Chemotherapy, 2006-04, Vol.50 (4), p.1570-1572

2006

Volltextzugriff (PDF)

Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals

American journal of health-system pharmacy, 2003-10, Vol.60 (19), p.1962-1970

2003

Volltextzugriff (PDF)

Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy

Antimicrobial Agents and Chemotherapy, 1998-03, Vol.42 (3), p.521-527

1998

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

Antimicrobial Agents and Chemotherapy, 2003-05, Vol.47 (5), p.1643-1646

2003

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia

Antimicrobial Agents and Chemotherapy, 2006-03, Vol.50 (3), p.994-1000

2006

Volltextzugriff (PDF)

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Antimicrobial Agents and Chemotherapy, 2005-01, Vol.49 (1), p.148-152

2005

Volltextzugriff (PDF)

Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus

American journal of health-system pharmacy, 2000-10, Vol.57 (suppl 2), p.S4-S9

2000

Volltextzugriff (PDF)

Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team

Antimicrobial Agents and Chemotherapy, 2003-01, Vol.47 (1), p.292-296

2003

Volltextzugriff (PDF)

Gemifloxacin for the Treatment of Respiratory Tract Infections: In Vitro Susceptibility, Pharmacokinetics and Pharmacodynamics, Clinical Efficacy, and Safety

Pharmacotherapy, 2005-05, Vol.25 (5), p.717-740

2005

Volltextzugriff (PDF)

Outcomes evaluation of patients with ESBL- and non–ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program

Diagnostic microbiology and infectious disease, 2006-03, Vol.54 (3), p.231-236

2006

Volltextzugriff (PDF)

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia

Diagnostic microbiology and infectious disease, 2000-03, Vol.36 (3), p.145-158

2000

Volltextzugriff (PDF)

Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi

Antimicrobial Agents and Chemotherapy, 2005-05, Vol.49 (5), p.1775-1781

2005

Volltextzugriff (PDF)

Clinical pharmacodynamics of quinolones

Infectious Disease Clinics of North America, 2003-09, Vol.17 (3), p.529-543

2003

Volltextzugriff (PDF)

The inoculum effect: Fact or artifact?

Diagnostic microbiology and infectious disease, 2004-12, Vol.50 (4), p.229-230

2004

Volltextzugriff (PDF)

Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States

Diagnostic microbiology and infectious disease, 2005, Vol.51 (1), p.31-37

2005

Volltextzugriff (PDF)

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

Diagnostic microbiology and infectious disease, 2004-10, Vol.50 (2), p.95-102

2004

Volltextzugriff (PDF)

Use of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary Sinusitis

Clinical infectious diseases, 2004-06, Vol.38 (11), p.1513-1520

2004

Volltextzugriff (PDF)

Assessment of pharmacokinetic–pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae

Diagnostic microbiology and infectious disease, 2005, Vol.51 (1), p.45-49

2005

Volltextzugriff (PDF)

Relationships between Patient- and Institution-Specific Variables and Decreased Antimicrobial Susceptibility of Gram-Negative Pathogens

Clinical infectious diseases, 2003-08, Vol.37 (3), p.344-350

2003

Volltextzugriff (PDF)

Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables

Antimicrobial Agents and Chemotherapy, 2006-01, Vol.50 (1), p.62-67

2006

Volltextzugriff (PDF)

Benchmarking in health-system pharmacy: current research and practical applications

American journal of health-system pharmacy, 2000-10, Vol.57 (suppl 2), p.S13-S20

Bhavnani, SM

2000

Volltextzugriff (PDF)

Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility

American journal of health-system pharmacy, 1999-11, Vol.56 (21), p.2217-2223

1999

Volltextzugriff (PDF)

Pharmacodynamics in the evaluation of drug regimens

The Annals of pharmacotherapy, 2002-03, Vol.36 (3), p.530-532

2002

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

New agents for Gram-positive bacteria

Gatifloxacin and the elderly: pharmacokinetic–pharmacodynamic rationale for a potential age-related dose reduction

Voriconazole Therapeutic Drug Monitoring

Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals

Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy

Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus

Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team

Gemifloxacin for the Treatment of Respiratory Tract Infections: In Vitro Susceptibility, Pharmacokinetics and Pharmacodynamics, Clinical Efficacy, and Safety

Outcomes evaluation of patients with ESBL- and non–ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia

Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi

Clinical pharmacodynamics of quinolones

The inoculum effect: Fact or artifact?

Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

Use of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary Sinusitis

Assessment of pharmacokinetic–pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae

Relationships between Patient- and Institution-Specific Variables and Decreased Antimicrobial Susceptibility of Gram-Negative Pathogens

Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables

Benchmarking in health-system pharmacy: current research and practical applications

Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility

Pharmacodynamics in the evaluation of drug regimens

Suchergebnisse filtern